PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway

YU REN1*, XUAN ZHOU2*, YANBIN QI1*, GUOLAN LI1, MEI MEI1 and ZHI YAO3

1Tianjin Research Center of Basic Medical Science, Tianjin Medical University, Tianjin 300070; 2The First Department of Head and Neck Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060; 3Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry, Department of Immunology, Tianjin Medical University, Tianjin 300070, P.R. China

Received February 28, 2012; Accepted May 14, 2012

DOI: 10.3892/or.2012.1856

Abstract. Combination therapy is considered a promising therapeutic modality in enhancing treatment efficacy. The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is almost universally dysregulated in breast cancer, with specific occurrence of PTEN mutations; thus, it has become an attractive target for cancer treatment. However, the use of single targeted therapeutics against the PI3K/AKT pathway has demonstrated only modest clinical benefits. In this study, recombinant adenovirus-mediated gene transfer of PTEN (AD-PTEN) combined with treatment with LY294002 was utilized to evaluate the effects of suppression of breast cancer cell proliferation. Herein, we show that AD-PTEN significantly enhanced the sensitization of breast cancer cells to LY294002. The 50% inhibitory concentration (IC50) values of LY294002 were significantly decreased to a greater extent in cells transfected with combination therapy. In addition, treatment of AD-PTEN-transfected cells with LY294002 resulted in significantly reduced cell viability and invasion ability compared to single LY294002 treatment. Using western blotting, we found that combination treatment resulted in lower levels of phosphorylated AKTSer473 and GSK-3βSer9 than single treatment with LY294002. Furthermore, we showed a significant decrease in nuclear β-catenin, Fra-1, Tcf-4 and c-Myc by combination treatment. Our results indicate that AD-PTEN sensitization of breast cancer to LY294002 is achieved by increased GSK-3β activity, thus resulting in inhibition of the β-catenin signaling pathway.

Introduction

Breast cancer is a devastatingly common disease in women worldwide and there is a considerable need to improve approaches for prevention, diagnosis and treatment. Despite conventional treatments, including surgical resection, radiation therapy and chemotherapy, frequent tumor recurrence results in poor prognosis (1).

The phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays an important role in the biology of human cancers. Components of this pathway are frequently deregulated in a wide range of tumors, making them attractive targets for cancer therapy (2,3). Inhibitors of PI3K and AKT have undergone preclinical evaluation with encouraging results (4,5).

PTEN, one of the most frequently mutated tumor suppressor genes in human cancer, shows a very high frequency of mutations in tumor cells (6). Recent studies have shown that the frequencies of breast cancer cases associated with a loss of PTEN expression are 30% in primary tumors and 25% in metastatic tumors (7). Loss of PTEN function leads to increased concentrations of PIP3, resulting in constitutive activation of downstream components of the PI3K pathway, including AKT and mTOR (8).

LY294002, a classic PI3K inhibitor, is widely used to study the PI3K/AKT signaling pathway, and has strong antitumor activity (9-11). However, most clinical trials of low-molecular-weight kinase inhibitors as monotherapies have failed to demonstrate survival benefits in cancer patients. In response, combination therapy is considered a promising therapeutic model in overcoming therapeutic resistance and enhancing treatment efficacy.

In this study, adenovirus-mediated gene transfer of PTEN (AD-PTEN) was combined with LY294002 treatment and was utilized to evaluate its effect on the cell proliferation, cell cycle, invasion and migration in MCF-7 breast cancer cells. The addition of AD-PTEN reduced the 50% inhibitory concentration (IC50) value and enhanced the antitumor effect of

Correspondence to: Dr Mei Mei, Tianjin Research Center of Basic Medical Science, Tianjin Medical University, Tianjin 300070, P.R. China
E-mail: meim11@yahoo.com.cn

Dr Zhi Yao, Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry, Department of Immunology, Tianjin Medical University, Tianjin 300070, P.R. China
E-mail: yaozhi@tjmu.edu.cn

*Contributed equally

Key words: PTEN, LY294002, β-catenin pathway, phosphatidylinositol 3-kinase/AKT pathway, breast cancer
LY294002. In addition, combination therapy resulted in lower levels of phosphorylated AKTSer473 and GSK-3βSer9 than single treatment with LY294002. Several members of the Wnt/β-catenin pathway, including Tcf-4, Fra-1, c-Myc, and cyclin D1, were dysregulated in combination therapy. Furthermore, intratumoral administration of LY294002 to subcutaneous LN229 xenograft tumors delayed tumor growth. Our results indicated that the synergistic cytotoxic effect of AD-PTEN and LY294002 is achieved by the inhibition of Wnt/β-catenin signaling pathway.

Materials and methods

Cell culture. Human breast adenocarcinoma MCF-7 cells were provided by Wuhan University Cell Center (Wuhan, China). Cell cultures were incubated at 37°C in a 5% CO2 atmosphere and routinely maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine (Invitrogen, Carlsbad, CA).

Reagents. Recombinant adenoviral vectors containing wild-type PTEN (PTEN sequence, AACTGCTCACCGGAAT) were constructed by the Chinese National Human Genome Center (Beijing, China), at a concentration of 1x10¹⁰ IU/ml. LY294002 was purchased by Promega. Antibodies against PTEN, P13K, AKT, p-AKTSer473, GSK-3β, p-GSK-3βSer9, β-catenin, p-β-cateninSer33, Fra-1, Tcf-4, c-myc, PCNA, Bcl-2, cyclin D1, MMP-2 and MMP-9 were from Santa Cruz Center (Beijing, China), at a concentration of lx10⁶ IU/ml. AD-PTEN or LY294002 and AD-PTEN combined. Mice were sacrificed on Day 28 after tumor cell injections. Tumor growth was assessed weekly by measuring the two greatest perpendicular tumor diameters. Tumor volume was calculated as: tumor volume (mm³) = (tumor length (mm) x tumor width (mm²))/2.

Immunohistochemistry. Following sacrifice, tumor tissue was removed from the mice and fixed with 4% formaldehyde for 24 h. Immunostaining was performed on paraffin sections of tumor specimens using the avidin-biotin complex (ABC) method. Briefly, sections were incubated with primary antibody (dilution, 1:200) overnight at 4°C, then incubated with a biotinylated secondary antibody (dilution, 1:100) at room temperature for 1 h, followed by incubation with ABC-peroxidase reagent and DAB (diaminobenzidine), counterstaining with hematoxylin and visualization under the microscope.

Statistical analysis. Data are expressed as the mean ± SE. Statistical significance was determined using ANOVA, χ² test, or Student's t-test using SPSS13.0. Statistical significance was determined at P<0.05.
Results

**AD-PTEN increases LY294002 cytotoxicity in MCF-7 cells.** The results indicated that LY294002 can decrease the proliferation of MCF-7 cells, and addition of AD-PTEN can increase the sensitivity of cells to LY294002 treatment. Fig. 1A shows that the LY294002 concentration causing 50% growth inhibition (IC\(_{50}\)) of MCF-7 cells is 23.7 µmol/l; whereas, in combination with AD-PTEN the IC\(_{50}\) was 14.6 µmol/l.

To evaluate the synergistic effect of LY294002 and AD-PTEN on cell proliferation, we performed MTT assays in MCF-7 cells transfected with AD-PTEN or treated with LY294002 alone, or both transfected with AD-PTEN and treated with LY294002. Measurements were taken 48 h after transfection. The data from triplicate samples were analyzed for differences by unpaired, two-tailed t-tests. As indicated, LY294002 alone exhibited a moderate suppressive effect in the first three days of the MTT assay, resulting in maximal inhibition of 60% in MCF-7 cells (Fig. 1B). The combination of LY294002 and AD-PTEN appeared to show increased suppressive effects in MTT assays. Co-delivery of LY294002 and AD-PTEN consistently maintained the best suppressive effect during the entire MTT assay and resulted in maximal inhibition of 38% during the six days.

To better understand the synergistic effects on cell cycle progression, we exposed the cells to LY294002 and AD-PTEN alone or in combination, and evaluated changes in cell cycle distribution by flow cytometry analysis (Fig. 1C). Untreated cells served as negative controls. Fig. 1C shows a representative experiment in which 61% of cells treated with LY29004 were in G\(_0\)/G\(_1\)-phase, whereas treatment with LY294002 and AD-PTEN resulted in 74% of cells in G\(_0\)/G\(_1\) phase.

Subsequently, we would like to further explore whether the effects of LY294002 combined with AD-PTEN had any effect on the expression of a set of proteins that are important for cell proliferation and survival. Proliferating cell nuclear antigen (PCNA) is a critical event in growth regulation of breast cancer cells, which acted as a molecular platform to recruit proteins involved in DNA synthesis, cell cycle control, and DNA-damage response and repair. In the current study, a significant decrease in the level of PCNA expression could be observed in the combination treatment group (Fig. 1E). The protein level of PCNA revealed a 5.8-fold reduction in the LY294002-alone-treated cells, and a 7.6-fold reduction in cells treated with LY294002 and AD-PTEN resulted in 74% of cells in G\(_0\)/G\(_1\) phase.

Cyclin D1 is a critical mitogen-regulated cell cycle control element whose transcriptional modulation plays a crucial role in breast cancer growth and progression. The protein level of
cyclin D1 revealed a 4.2-fold reduction in single LY294002-treated cells and a 5.8-fold decrease in the combined treatment group, respectively (Fig. 1E). These findings indicate that, at least in vitro, AD-PTEN sensitizes breast cancer cells to LY294002 cytotoxicity.

LY294002 and AD-PTEN combination therapy regulates cell invasion and migration. To measure the effects of LY294002 combined with AD-PTEN on breast cancer cell invasiveness and migration, we employed the transwell invasion assay and a xenograft model, which are better indicators of cancer migratory and invasive properties in vitro. Transwell assays consist of two fluid-filled, stacked compartments separated by a porous membrane filter coated with matrigel. Cells were grown in the upper chamber and assessed for invasion through the matrigel toward a chemo-attractant (10% serum) in the lower chamber. The number of invasive cells in cultures treated with LY294002 and AD-PTEN was reduced relative to the control cells without any treatment (Fig. 2A); a decrease of 65 to 31-35 MCF-7 cells. The number of invasive cells in cultures with combination treatment was significantly reduced relative to the cells treated with LY294002 or AD-PTEN alone (Fig. 2B); a decrease from 31-35 to 10 MCF-7 cells.

The number of migrating cells in LY294002 and AD-PTEN combination treatment group were 43 (Fig. 2C), which was significantly fewer than the LY294002 treated group (n=134), the AD-PTEN treated group (n=102) and the control group (n=352).

Proteins of the matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix, which contributes to tumor cell invasion of normal tissues and metastasis. In this respect, the levels of expression of TIMP-3 and MMP-9 proteins after combination treatments were evaluated by western blotting (Fig. 2D). Significantly decreased expression of was observed after treatment with LY294002 combined with AD-PTEN, while the level of TIMP-3 protein was dramatically enhanced in the combination treatment group compared to the single LY294002-treated group.

Combination treatment with LY294002 and AD-PTEN significantly decreases AKT$^{Ser473}$ and GSK-3β$^{Ser9}$ phosphorylation in breast cancer cells. To understand the molecular mechanisms by which LY294002 combined with AD-PTEN resulted in decreased proliferation, invasion and migration in MCF-7 breast cancer cells, the levels of phosphorylated AKT$^{Ser473}$ and GSK-3β$^{Ser9}$ were compared after 12-h single or combined treatment with LY294002 or/and AD-PTEN. As shown in Fig. 3, both phosphorylated AKT$^{Ser473}$ and GSK-3β$^{Ser9}$ were decreased by single LY294002 treatment or single AD-PTEN treatment. After combination treatment with LY294002 and AD-PTEN, both phosphorylated AKT$^{Ser473}$ and GSK-3β$^{Ser9}$ were significantly decreased.

To detect whether decreased proliferation, invasion and migration in MCF-7 breast cancer cells caused by combined treatment of LY294002 and AD-PTEN was modulated by GSK-3β/β-catenin signaling pathway, cell cycle regulators
such as c-Myc and cyclin D1, and transcription factors such as Fra-1 and Tcf-4, were measured by western blotting. As shown in Fig. 3, combined treatment could significantly inhibit downstream β-catenin signal transduction pathways, compared with LY294002 or AD-PTEN single treatments.

**LY294002 combined with AD-PTEN suppresses breast cancer growth in the xenograft model.** LY294002 combined with AD-PTEN demonstrated an excellent tumor suppressive effect and may be a potential therapy for human breast cancer. To further confirm this hypothesis, four experimental groups were examined in an MCF-7 xenograft model: i) control, ii) LY294002, iii) AD-PTEN and iv) combined AD-PTEN and LY294002 therapy groups. At the beginning of treatment, the mean tumor volumes of the mice in LY294002 and AD-PTEN treated groups alone or in combination were 120, 127 and 136 mm$^3$, respectively, with no statistically significant differences among these three groups. The mice were monitored every 4 days for 4 weeks, and the tumor volume of mice in each group was measured and compared. At the end of the experiment, significant decreases in tumor volume was only observed in the combination treatment group; the tumor volume was greatly reduced compared with the LY294002 group (763 mm$^3$ vs. 1789 mm$^3$ and 1433 mm$^3$, P<0.01). Consistent with the *in vitro* results, we observed decreased expression of phosphorylated AKT as well as PCNA, cyclin D1 and MMP-9 in the combination-treated tumors (Fig. 4B).

**Discussion**

Selection of appropriate combinations of anticancer agents that can exert synergistic cytotoxic interactions has been widely adopted and utilized in preclinical and clinical studies. Yang *et al* (12) revealed that temsirolimus treatment combined with either BEZ235 (a dual PI3K/mTOR inhibitor) or ZSTK474 (a pan PI3K inhibitor) inhibited phosphorylation of both 4E-BP1 and the substrate for S6K, ribosomal S6 (rS6), which ultimately resulted in synergistic cell death of six endometrial cancer cell lines. Morelli *et al* (13) demonstrated that dual inhibition of MAPK signaling and HDAC activity resulted in inhibition of several colorectal cancer biological processes, which was mediated by an increased level of caspase 3/7 activity, cleaved PARP and perhaps increased acetylated histone H3 levels. Recent studies in human gastric cancer indicated that DLL4 inhibitor combined with Jagged1-siRNA gene therapy mediated by adenovirus can enhance inhibition of SGC7901 human gastric cancer cell proliferation and invasion through the DLL4/ Jagged1-Notch1 pathway (14).

Despite the availability of several active combination regimens for breast cancer, the 5-year survival rate remains poor, supporting the development of novel therapeutic approaches. The PI3K/AKT signaling pathway is almost universally dysregulated in breast cancer, with specific occurrence of PTEN mutations, which results in overactivation of PI3K/AKT signaling and its downstream signal transduction pathways (15,16). Therefore, it has become an attractive target for cancer treatment and as a result, inhibition of this pathway is a major strategy for cancer therapy.

However, single-targeted therapeutics against the PI3K/AKT pathway have demonstrated only modest clinical benefits. In the present study, we compared the pro-apoptotic effect of treatment with LY294002, a specific PI3K inhibitor, and AD-PTEN, a recombinant adenovirus-PTEN, alone or in combination. Our results revealed that AD-PTEN significantly reduced the IC$_{50}$ of LY294002 concentration by ~2-fold compared to LY294002 alone. Cell proliferation, migration, and invasion ability were
also dramatically inhibited by combination treatment compared to individual LY294002 or AD-PTEN treatment.

To understand the underlying molecular mechanisms, we then investigated the activation of downstream effectors of the PI3K signaling pathway. Expression of total AKT was not changed, while p-AKTSer473 levels were dramatically decreased in combination therapy compared to LY294002 alone. Importantly, combined treatment resulted in lower levels of phosphorylation GSK-3βSer9, β-catenin, c-Myc and Tcf-4 (Fig. 3). GSK-3β is the main target for AKT and is inhibited by AKT phosphorylation. In the Wnt/β-catenin signaling pathway, GSK-3β directly determines the stabilization of β-catenin by phosphorylation (17). As a result, there is an accumulation of stabilized hypo-phosphorylated β-catenin, which then translocates to the nucleus and associates with transcription factors of the Lef/Tcf family to initiate the expression of a broad range of genes, such as c-Myc and cyclin D1. Thus, our data indicated that the Wnt/β-catenin signaling pathway may be responsible for the synergistic cytotoxic effect mechanism of LY294002 and AD-PTEN.

We showed for the first time that inactivation of PI3K/AKT represses β-catenin-mediated transcription in breast cancer. Indeed, this hypothesis of cross-talk between the β-catenin and PI3K/AKT signaling pathways might have supportive evidence. Damsky et al. (18) demonstrated that β-catenin is a central mediator of melanoma metastasis to the lymph nodes and lungs, controls tumour differentiation and regulates both MAPK/ERK and PI3K/AKT signaling. In U87MG cells, Zhang et al. (19) also showed that the activation of Notch1 by DLL4 stimulation or by the overexpression of Notch intracellular domain (NICD) resulted in AKT activation, thereby promoting β-catenin activity. It has also been reported that the cooperation between Wnt/β-catenin and PTEN/PI3K/AKT signaling promotes primitive hematopoietic stem cell self-renewal and expansion (20).

Taken together, our data demonstrate that AD-PTEN significantly enhances the sensitization of breast cancer cells to LY294002. We also showed that increased GSX-3β activity resulting in the inhibition of β-catenin signaling pathway may be responsible for the synergistic cytotoxic effect of LY294002 and AD-PTEN. Thus, inhibition of PI3K was proven to be an effective strategy for inactivation of the Wnt/β-catenin pathway. Furthermore, we also showed for the first time that cross-talk between PI3K/AKT and Wnt/β-catenin pathway occurs in breast cancer. The findings of the present study might help guide the development of potential therapeutic targets for the treatment of breast cancer patients.

Acknowledgements

This study was financially supported by the 973 Programme Grant (2009CB918903, 2011CB933100) from the Ministry of Science and Technology of China, the China National Natural Scientific Fund (51073118, 81101916, 51103107), the Tianjin Science and Technology Committee (10JCYBJC12500,10JCZDJC19700), and the Program for New Century Excellent Talents in University (NCET-08-0393).

References